Please provide your email address to receive an email when new articles are posted on . Lenalidomide maintenance therapy significantly improved PFS compared with observation among patients with newly ...

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant ...

Data from a large phase III trial presented at the 2022 American Society of Hematology (ASH) annual meeting examined the relationship between minimal residual disease, progression-free survival, and ...

Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación ...

From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients. Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) lived twice as long when treated with ...

Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma.

The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...

Background. A 51-year-old man presented with an 8 month history of migratory pain and weakness. Investigations. Conventional X-ray, MRI, laboratory investigations including serum electropheresis and ...

REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous ...